Early diagnosis of diabetic nephropathy and its screening

  • Nasser Abdel Polanco Flores Servicio de Nefrología, Hospital General Guillermo Álvarez Macías, Tula de Allende, Hidalgo
  • Francisco Rodríguez Castellanos
Keywords: diabetic nephropathy, diabetes mellitus type 2, renal insufficiency chronic, mass screening, albuminuria, cribado

Abstract

Introduction: Diabetic nephropathy constitutes the leading cause of chronic kidney disease and renal function substitution all over the world and without exception, given the rapid deterioration of renal function suffered by patients who fail to achieve diabetes metabolic control goals and the associated comorbidities representing additional progression factors. All these cause an unavoidable drop in glomerular filtration rate and a subsequent dialysis treatment. Considering that nowadays there are not any preventive interventions in nephrology focused on diabetes, we present the results of a program conducted on patients treated for the first time at Hospital General Guillermo Álvarez Macías, Tula de Allende, Hidalgo, México. Objective: Early diagnosis of diabetic nephropathy and identification of associated risk factors. Methods: A descriptive, retrospective, cross-sectional study, which included a 24-hour albumin test, was conducted by means of renal function tests deliberately looking for abnormal findings. Data were analyzed using the SPSS 15 statistical software for Windows. Results: By means of traditional techniques used to treat diabetic patients in general, it was possible to diagnose diabetic nephropathy in 61% of the patients vs. 30%. Persistent hyperglycemia was found to be the main factor associated with nephropathy, lengthy suboptimal control levels being the common factor that distinguishes these patients from the population not suffering from diabetic nephropathy (p 0.002). Conclusions: Given that diabetic nephropathy is a preventable disease, it is easy to diagnose it through an adequate screening at first- and second-level care, which allows a timely referral to a nephrology specialist to treat it.

References

Eckardt KU, Coresh J, Devuyst O, Johnson RJ, Köttgen A, Levey AS, et al. Evolving importance of kidney disease: from subspecialty to global health burden. Lancet. 2013;382(9887):158-69.

Unites States Renal Data System. Annual Data Report 2012 [Internet]. Disponible en: https://www.usrds.org/adr.aspx (citado: 22/08/2017).

Registro Español de Enfermos Renales. Informe de Diálisis y Trasplante 2016. Sociedad Española de Nefrología, 2017. 75 p. Disponible en: http://www.senefro.org/contents/webstructure/InformeREER_2016_BURGOS.pdf (citado: 22/08/2017).

Méndez-Durán A, Méndez-Bueno JF, Tapia-Yáñez T, Muñoz Montes A, Aguilar-Sánchez L. Epidemiología de la insuficiencia renal crónica en México. Dial Traspl. 2010;31(1):7-11.

Wild S, Roglic G, Green A, Sicree R, King H. Global prevalence of diabetes: estimates for the year 2000 and projections for 2030. Diabetes Care. 2004;27(5):1047-53.

Gheith O, Farouk N, Nampoory N, Halim MA, Al-Otaibi T. Diabetic kidney disease: world wide difference of prevalence and risk factors. J Nephropharmacol. 2015;5(1):49-56.

Mogensen CE. Microalbuminuria, blood pressure and diabetic renal disease: origin and development of ideas. Diabetologia. 1999;42(3):263-85.

Kowalski A, Krikorian A, Lerma EV. Diabetic nephropathy for the primary care provider: new understandings on early detection and treatment. Ochsner J. 2014;14(3):369-79.

Kramer H, Molitch ME. Screening for kidney disease in adults with diabetes. Diabetes Care. 2005;28(7):1813-6.

Ruospo M, Saglimbene VM, Palmer SC, De Cosmo S, Pacilli A, Lamacchia O, et al. Glucose targets for preventing diabetic kidney disease and its progression. Cochrane Database Syst Rev. 2017;6:CD010137.

MacIsaac RJ, Jerums G, Ekinci EI. Effects of glycaemic management on diabetic kidney disease. World J Diabetes. 2017;8(5):172-86.

Yokoyama H, Okudaira M, Otani T, Sato A, Miura J, Takaike H, et al. Higher incidence of diabetic nephropathy in type 2 than in type 1 diabetes in early-onset diabetes in Japan. Kidney Int. 2000;58(1):302-11.

Hasslacher C, Ritz E, Wahl P, Michael C. Similar risks of nephropathy in patients with type I or type II diabetes mellitus. Nephrol Dial Transplant. 1989;4(10):859-63.

Tan J, Zwi LJ, Collins JF, Marshall MR, Cundy T. Presentation, pathology and prognosis of renal disease in type 2 diabetes. BMJ Open Diabetes Res Care. 2017;5(1):e000412.

Fioretto P, Mauer SM, Bilous RW, Goetz FC, Sutherland DE, Steffes MW. Effects of pancreas transplantation on glomerular structure in insulin-dependent diabetic patients with their own kidneys. Lancet. 1993;342(8881):1193-6.

Fioretto P, Mauer M. Reversal of diabetic nephropathy: lessons from pancreas transplantation. J Nephrol. 2012;25(1):13-8.

Fioretto P, Barzon I, Mauer M. Is diabetic nephropathy reversible? Diabetes Res Clin Pract. 2014;104(3):323-8.

Lackland DT6, LeFevre ML7, MacKenzie TD8, Ogedegbe O9, Smith SC Jr10, Svetkey LP11, Taler SJ12, Townsend RR13, Wright JT Jr14, Narva AS15, Ortiz E16. 2014 evidence-based guideline for the management of high blood pressure in adults: report from the panel members appointed to the Eighth Joint National Committee (JNC 8). JAMA. 2014;311(5):507-20. Erratum in JAMA. 2014;311(17):1809.

Published
2018-12-14
How to Cite
1.
Polanco Flores NA, Rodríguez Castellanos F. Early diagnosis of diabetic nephropathy and its screening. Rev Nefrol Dial Traspl. [Internet]. 2018Dec.14 [cited 2024Dec.28];38(4):258-67. Available from: http://vps-1689312-x.dattaweb.com/index.php/rndt/article/view/372
Section
Original Article